US2004053316A1PendingUtilityA1
Methods and compositions for the selective modification of nucleic acids
Est. expiryOct 3, 2017(expired)· nominal 20-yr term from priority
C12N 2760/16163C12N 2795/10163A61P 43/00C12N 2770/32363C12N 2740/16063C12N 2770/32463C12N 2760/20263C12N 7/00A61P 31/12A61P 31/00A61L 2/18A61L 2/16A61L 2103/05
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 cannot all be H; R 5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 cannot all be H; R 5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
2 . The method of claim 1 , wherein R 5 is alkylene and each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is, independently, H or alkyl.
3 . The method of claim 1 , wherein R 5 contains 3 carbon atoms.
4 . The method of claim 1 , wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is H or a linear alkyl group.
5 . The method of claim 1 , wherein at least two of R 1 , R 2 , R 3 , and R 4 are H.
6 . The method of claim 1 , wherein at least three of R 1 , R 2 , R 13 , and R 4 are H.
7 . The method of claim 1 , wherein X is selected from the group consisting of chloride, bromide, iodide, acetate, and tosylate.
8 . The method of claim 1 , wherein n is 3 or 4.
9 . The method of claim 1 , wherein said biological composition is a cell-containing composition.
10 . The method of claim 1 , wherein said biological composition is selected from the group consisting of mammalian blood, purified or partially purified blood proteins, purified or partially purified blood components, blood cell proteins, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of plasma, a supernatant from any fractionation of plasma, milk, saliva, serum, a cryoprecipitate, a cryosupernatant, a cell lysate, mammalian cell culture, mammalian cell culture medium, placental extracts, products of fermentation, ascitic fluid, and proteins induced in blood cells.
11 . The method of claim 1 , wherein the nucleic acid molecules are contained within a transforming DNA fragment.
12 . The method of claim 1 , wherein said nucleic acid molecules are contained within an infectious vertebrate virus.
13 . The method of claim 12 , wherein the virus is selected from the group consisting of poxviruses, herpes viruses, adenoviruses, rubiviruses, flaviviruses, coronaviruses, paramyoxviruses, morbilliviruses, pneumonviruses, vesiculoviruses, lyssaviruses, picornaviruses, orthomyxoviruses, bunyaviruses, phleboviruses, nairoviruses, hepadnaviruses, arenaviruses, retroviruses, enteroviruses, rhinovirus, and the filoviridae.
14 . The method of claim 12 , wherein the virus is an enveloped virus.
15 . The method of claim 12 , wherein the virus is a non-enveloped virus.
16 . The method of claim 12 , wherein said inactivated virus comprises a killed virus vaccine.
17 . A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 cannot all be H; R 5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
18 . The killed vaccine of claim 17 , wherein the viral inactivating conditions are effective to diminish infectivity by at least 20 logs by calculation.
19 . A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 cannot all be H; R 5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
20 . A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
ω-X 1 —[R 1 —N + (R 2 , R 3 )—] n R 4 − (X 2 − ) n
wherein X 1 is Cl or Br; R 1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; each of R 2 , R 3 , and R 4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 2 , R 3 , and R 4 cannot all be H when R 1 contains 2 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
21 . The method of claim 20 , wherein R 1 is alkylene and each of R 2 , R 3 , and R 4 is, independently, H or alkyl.
22 . The method of claim 20 , wherein R 1 contains 3 carbon atoms.
23 . The method of claim 20 , wherein each of R 2 , R 3 , and R 4 is H or a linear alkyl group.
24 . The method of claim 20 , wherein X 2 is selected from the group consisting of chloride, bromide, acetate, and tosylate.
25 . The method of claim 20 , wherein n is 3 or 4.
26 . The method of claim 20 , wherein said biological composition is a cell-containing composition.
27 . The method of claim 20 , wherein the nucleic acid molecules are contained within a transforming DNA fragment.
28 . The method of claim 20 , wherein said nucleic acid molecules are contained within an infectious vertebrate virus.
29 . The method of claim 28 , wherein the virus is an enveloped virus.
30 . The method of claim 28 , wherein the virus is a non-enveloped virus.
31 . The method of claim 28 , wherein said inactivated virus comprises a killed virus vaccine.
32 . A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
ω-X 1 —[R 1 —N + (R 2 , R 3 )—] n R 4 − (X 2 − ) n
wherein X 1 is Cl or Br; R 1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; each of R 2 , R 3 , and R 4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 2 , R 3 , and R 4 cannot all be H when R 1 contains 2 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
33 . The killed vaccine of claim 32 , wherein the viral inactivating conditions are effective to diminish infectivity by at least 20 logs by calculation.
34 . A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
ω-X 1 —[R 1 —N + (R 2 , R 3 )—] n R 4 − (X 2 − ) n
wherein X 1 is Cl or Br; R 1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; each of R 2 , R 3 , and R 4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 2 , R 3 , and R 4 cannot all be H when R 1 contains 2 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
35 . A nucleic acid inactivating agent having the formula:
ω-X 1 —[R 1 —N + (R 2 , R 3 )—] n R 4 − (X 2 − ) n
wherein X 1 is Cl or Br; R 1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; each of R 2 , R 3 , and R 4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R 2 , R 3 , and R 4 cannot all be H when R 1 contains 2 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
36 . The inactivating agent of claim 35 , wherein R 1 is alkylene and each of R 2 , R 3 , and 4 is, independently, H or alkyl.
37 . The inactivating agent of claim 35 , wherein R 1 contains 3 carbon atoms.
38 . The inactivating agent of claim 35 , wherein each of R 2 , R 3 , and R 4 is H or a linear alkyl group.
39 . The inactivating agent of claim 35 , wherein X 2 is selected from the group consisting of chloride, bromide, acetate, and tosylate.
40 . A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
β-X 1 —CH 2 CH 2 —N + H(R 1 )—[R 2 —N + (R 3 , R 4 )—] n R 5 − (X 2 − ) n+1
wherein X 1 is Cl or Br; each of R 1 , R 3 , R 4 , and R 5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive; R 2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
41 . The method of claim 40 , wherein each of R 1 , R 3 , R 4 , and R 5 is, independently, H or alkyl, and R 2 is alkylene.
42 . The method of claim 40 , wherein R 2 contains 3 carbon atoms.
43 . The method of claim 40 , wherein each of R 1 , R 3 , R 4 , and R 5 is H or a linear alkyl group.
44 . The method of claim 40 , wherein n is 3 or 4.
45 . The method of claim 40 , wherein X 2 is selected from the group consisting of chloride, bromide, acetate, and tosylate.
46 . The method of claim 40 , wherein said biological composition is a cell-containing composition.
47 . The method of claim 40 , wherein the nucleic acid molecules are contained within a transforming DNA fragment.
48 . The method of claim 40 , wherein said nucleic acid molecules are contained within an infectious vertebrate virus.
49 . The method of claim 48 , wherein the virus is an enveloped virus.
50 . The method of claim 48 , wherein the virus is a non-enveloped virus.
51 . The method of claim 48 , wherein said inactivated virus comprises a killed virus vaccine.
52 . A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
β-X 1 —CH 2 CH 2 —N + H(R 1 )—[R 2 —N + (R 3 , R 4 )—] n R 5 − (X 2 − ) n+1
wherein X 1 is Cl or Br; each of R 1 , R 3 , R 4 , and R 5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive; R 2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
53 . The killed vaccine of claim 52 , wherein the viral inactivating conditions are effective to diminish infectivity by at least 20 logs by calculation.
54 . A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
β-X 1 —CH 2 CH 2 —N + H(R 1 )—[R 2 —N + (R 3 , R 4 )—]R 5 − (X 2 − ) n+1
wherein X 1 is Cl or Br; each of R 1 , R 3 , R 4 , and R 5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive; R 2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
55 . A nucleic acid inactivating agent having the formula:
β-X 1 —CH 2 CH 2 —N + H(R 1 )—[R 2 —N + (R 3 , R 4 )—] n R 5 − (X 2 − ) n+1
wherein X 1 is Cl or Br; each of R 1 , R 3 , R 4 , and R 5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive; R 2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms; X 2 is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive.
56 . The inactivating agent of claim 55 , wherein each of R 1 , R 3 , R 4 , and R 5 is, independently, H or alkyl, and R 2 is alkylene.
57 . The inactivating agent of claim 55 , wherein R 2 contains 3 carbon atoms.
58 . The inactivating agent of claim 55 , wherein each of R 1 , R 3 , R 4 , and R 5 is H or linear alkyl.
59 . The inactivating agent of claim 55 , wherein n is 3 or 4.
60 . The inactivating agent of claim 55 , wherein X 2 is selected from the group consisting of chloride, bromide, acetate, and tosylate.Join the waitlist — get patent alerts
Track US2004053316A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.